- Home
- HBAN vs IQV Comparison
HBAN vs IQV Comparison
Compare HBAN & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBAN
- IQV
- Stock Information
- Founded
- HBAN 1866
- IQV 1982
- Country
- HBAN United States
- IQV United States
- Employees
- HBAN N/A
- IQV N/A
- Industry
- HBAN Major Banks
- IQV Biotechnology: Commercial Physical & Biological Resarch
- Sector
- HBAN Finance
- IQV Health Care
- Exchange
- HBAN Nasdaq
- IQV Nasdaq
- Market Cap
- HBAN 26.0B
- IQV 31.0B
- IPO Year
- HBAN N/A
- IQV 2013
- Fundamental
- Price
- HBAN $17.63
- IQV $187.76
- Analyst Decision
- HBAN Buy
- IQV Strong Buy
- Analyst Count
- HBAN 17
- IQV 19
- Target Price
- HBAN $18.78
- IQV $229.37
- AVG Volume (30 Days)
- HBAN 25.2M
- IQV 1.2M
- Earning Date
- HBAN 10-16-2025
- IQV 10-30-2025
- Dividend Yield
- HBAN 3.52%
- IQV N/A
- EPS Growth
- HBAN 26.38
- IQV N/A
- EPS
- HBAN 1.34
- IQV 6.92
- Revenue
- HBAN $7,242,000,000.00
- IQV $15,700,000,000.00
- Revenue This Year
- HBAN $18.05
- IQV $6.01
- Revenue Next Year
- HBAN $8.22
- IQV $5.05
- P/E Ratio
- HBAN $13.16
- IQV $27.11
- Revenue Growth
- HBAN 7.91
- IQV 3.60
- 52 Week Low
- HBAN $11.92
- IQV $134.65
- 52 Week High
- HBAN $18.45
- IQV $249.54
- Technical
- Relative Strength Index (RSI)
- HBAN 60.51
- IQV 53.87
- Support Level
- HBAN $17.42
- IQV $177.82
- Resistance Level
- HBAN $17.92
- IQV $192.13
- Average True Range (ATR)
- HBAN 0.33
- IQV 4.48
- MACD
- HBAN 0.07
- IQV -1.14
- Stochastic Oscillator
- HBAN 74.68
- IQV 54.02
About HBAN Huntington Bancshares Incorporated
Huntington is a regional US bank with around $208 billion in assets and has a large presence, particularly in the Midwestern market. It offers a full suite of consumer deposit and lending services, along with commercial services focused on payments, investment management, capital markets, equipment financing, treasury management, and other common banking services.
About IQV IQVIA Holdings Inc.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.